New Long-Acting numbing shot could ease pain after major abdominal surgery
NCT ID NCT07667439
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a long-acting numbing drug (liposomal bupivacaine) can reduce pain for up to 72 hours after open upper abdominal surgery. 148 adults having liver, stomach, or pancreatic surgery will get either the long-acting drug plus standard numbing, or standard numbing alone. The goal is to see if the long-acting version provides better and safer pain relief.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liposomal bupivacaine plus bupivacaine hydrochloride
What this could lead to
If it works, this could provide a longer-lasting, safer way to manage pain after major abdominal surgery, reducing the need for strong painkillers.
What could go wrong
This is a small, early-stage trial (148 people) at one hospital. The benefit may be small or not apply to all surgeries, and there is a risk of side effects like nausea or dizziness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTOPERATIVE ANALGESIA are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Contact Email: •••••@•••••
Contact